glp 1 california Medi-Cal halts GLP-1 obesity drug coverage California Ends Medicaid Coverage of
Description
Now What
Tirzepatide is the agonist of GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP) receptor, which can reduce body weight and improve cardiac metabolism by subcutaneous injection once a week (Jastreboff et al 2022)
Among the GLP-1 analogs, tirzepatide showed the most pronounced decrease in respiratory quotient (RQ) (Fig
After a real break, restarting means going back to a lower dose and stepping up again, the same way you started, so the side effects dont hit all at once
